Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immune function.
The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The pediatric regimen also includes 70 mg twice daily for children weighing at least 45 kilograms. Pharming Group N.V. (NASDAQ:PHAR) expects the new strengths in October through its existing distribution and patient-support network.
The expansion arrives as the revenue mix shifts. Second-quarter Joenja revenue increased 40% year over year to $17.9 million, while RUCONEST revenue declined 10% to $72.3 million. Total revenue fell 3% to $90.2 million. Joenja's growth is substantial, but the larger franchise still determines much of the overall result.
Pharming Group N.V. (NASDAQ:PHAR) can bring the pediatric doses to market through an established commercial platform. Distribution relationships and patient support are already in place, which could allow additional sales without duplicating the infrastructure required for an entirely new product.
The opportunity is to spread those capabilities across more eligible patients while maintaining support for existing users. Incremental revenue could improve commercial efficiency, although pediatric servicing costs will still matter.
#revenue #NASDAQ #joenja #pediatric
The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The pediatric regimen also includes 70 mg twice daily for children weighing at least 45 kilograms. Pharming Group N.V. (NASDAQ:PHAR) expects the new strengths in October through its existing distribution and patient-support network.
The expansion arrives as the revenue mix shifts. Second-quarter Joenja revenue increased 40% year over year to $17.9 million, while RUCONEST revenue declined 10% to $72.3 million. Total revenue fell 3% to $90.2 million. Joenja's growth is substantial, but the larger franchise still determines much of the overall result.
Pharming Group N.V. (NASDAQ:PHAR) can bring the pediatric doses to market through an established commercial platform. Distribution relationships and patient support are already in place, which could allow additional sales without duplicating the infrastructure required for an entirely new product.
The opportunity is to spread those capabilities across more eligible patients while maintaining support for existing users. Incremental revenue could improve commercial efficiency, although pediatric servicing costs will still matter.
#revenue #NASDAQ #joenja #pediatric
1 day ago
